Antiretroviral treatment during pregnancy - A help for making informed decision;Entscheidungs-grundlagen fur die antiretrovirale behandlung wahrend der schwangerschaft

Therapeutische Umschau

Volumn 55, Issue 5, 1998, Pages 323-328

  Malinverni, R ^a   Rudin, Ch ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; PROTEINASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; MEDICAL DECISION MAKING; ORAL DRUG ADMINISTRATION; PREGNANCY; REVIEW; RISK BENEFIT ANALYSIS; VERTICAL TRANSMISSION; ADULT; DECISION SUPPORT SYSTEM; DISEASE TRANSMISSION; NEWBORN; PREGNANCY COMPLICATION; RISK FACTOR;

ADULT; ANTI-HIV AGENTS; DECISION SUPPORT TECHNIQUES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; ZIDOVUDINE;

EID: 0031858878     PISSN: 00405930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Pädiatrische AIDS-Gruppe Schweiz (PAGS); Subkommission Klinik der Eidg. Kommission für AIDS-Fragen (EKAF); Arbeitsgruppe HIV der Schweizerischen Gesellschaft für Gynäkologie und Geburtshilfe: Zidovudin zur Prophylaxe der HIV-Übertragung von der infizierten Mutter auf ihr Kind. Schweiz. Ärztezeitung 75, 1508-1509, 1994.
2. Connor E. M., Sperling E. S., Gelber R. et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N. Engl. J. Med. 331, 1173-1180, 1994.
3. Cooper E. R., Nugent R. P., Diaz C. et al.: After Aids clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. J. Infect. Dis. 174, 1207-1211, 1996.
4. Fiscus S. A., Adimora A. A., Schoenbach V. J. et al.: Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 275, 1483-1488, 1996.
5. Blanche S., Mayaux M. J., Mandelbrot L. et al.: Acceptability and impact of zidovudine prevention on mother-child transmission in France. Proc. 4th Conf. on Retroviruses and Opportunistic infections. Washington DC, (abstract 380), 1997.
6. Havlir D. V. Richman D. D.: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann. Int. Med. 124, 984-994. 1996.
7. Subkommission Klinik der Eidg. Kommission für AidsFragen: Neue Empfehlungen zur Behandlung der HIV-Infektion bei Erwachsenen. BAG Bulletin 20, 9-10, 1997.
8. Hammer S. M., Squires K. E., Hughes M. D. et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337, 725-733, 1997.
9. Gulick R. M., Mellors J. W., Havlir D. et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337, 734-739, 1997.
10. Egger M., Hirschel B., Francioli P. et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospectige multicenter study. Br. Med. J. 315, 1194-1199, 1997.
11. Department of Health and Human Services: US: Public Health Service Task Force recommendations for use of antiretroviral drugs during pregnancy for maternal health and reduction of perinatal transmission of human immunodeficiency virus type 1 in the United States. MMWR 47 (RR-2), 1-30, 1998.
12. Mayaux M. J., Dussaix E., Isopet J. et al.: Maternal virus load during pregnancy and the mother to child transmission of human immunodeficiency virus type 1: the French perinatal Cohort study. J. Infect Dis. 175, 172-175, 1997.
13. Cao Y., Krogstad P., Korber B. T. et al.: Maternal HIV-1 viral load and vertical transmission of infection: The Ariel project for the prevention of HIV transmission from mother to infant. Nature Medicine 3, 549-552, 1997.
14. Thea D. M., Steketee R. W., Borshlegel K. et al.: The effect of maternal viral load on the risk of perinatal transmission of HIV-1. J. Infect Dis. 775, 707-711, 1997.
15. Sperling R. S., Shapiro D. E., Coombs R. W. et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus from mother to infant. N. Engl. J. Med. 335. 1621-1629, 1996.
16. Sandberg J. A., Slikker W. Jr: Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides. FASEB J. 9, 1157-1163, 1995.
17. Qian M., Bui T., Ho R. J. Y. et al.: Metabolism of 3'-azido-3'-deoxythymidine (AZT) in human placental trophoblasts and hofbauer cells. Biochem. Pharmacol. 48, 383-389, 1994.
18. Cu Uvin S., CaliendoA. M.: Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women. Obstet. Gynecol. 90, 739-743, 1997.
19. Frenkel L. M., Cowles M. K., Shapiro D. E. et al.: Analysis of the maternal components of the AIDS Clinical Trial Group 076 zidovudine regimen in the prevention of mother-to-infant transmission of human immunodeficiency virus type 1. J. Infect Dis. 175, 971-974, 1997.
20. Simpson B. J., Shapiro E. D., Andiman W. A.: Reduction in the risk of vertical transmission of HIV-1 associated with treatment of pregnant women with orally administered zidovudine alone. J. Acquir. Immune Defic. Syndr. Hum. Retroviruses 14, 145-152, 1997
21. Pädiatrische AIDS-Gruppe Schweiz (PAGS): Medizinische Kontrolle von Kindern HIV-positiver Mütter. Paediatrica 6, 11-13, 1995.